SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Emmaus Life Sciences, Inc. 
 CA
  SEC # 822370


        
1  Related Registrant:   

    Click to view...      Registrant      About      Filings      Files      Relationships      Names    
  Topics  
    Web       

85  Topics
Topic emoji
 within the 

Show:   Most-Recent Document   All Documents   And:   Exhibits  

 As Of  Filing  Doc.  Page    Title Docs.
  In ascending order
3/31/2310-K1Business
1Cautionary Statement Regarding Forward-Looking Statements
1Certain Relationships and Related Transactions, and Director Independence
1Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
1Consolidated Balance Sheets as of December 31, 2022 and 2021
1Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 202
1Consolidated Statements of Changes in Stockholders' Deficit for the Years Ended December 31, 2022 and 2021
1Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2022 and 2021
11/13/2310-Q1Controls and Procedures
1Defaults Upon Senior Securities
3/31/2310-K1Directors, Executive Officers and Corporate Governance
1Disclosure Regarding Foreign Jurisdictions That Prevent Inspections
1Executive Compensation
11/13/2310-Q1Exhibits
3/31/2310-K1Exhibits and Financial Statement Schedules
11/13/2310-Q1Financial Statements (Unaudited)
3/31/2310-K1Financial Statements and Supplementary Data
11/13/2310-Q1Legal Proceedings
1Management's Discussion and Analysis of Financial Condition and Results of Operations
3/31/2310-K1Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
11/13/2310-Q1Mine Safety Disclosures
3/31/2310-K1Notes to Consolidated Financial Statements
11/13/2310-Q1Other Information
3/31/2310-K1Part I
1Part Ii
1Part Iii
1Part Iv
1Principal Accounting Fees and Services
1Properties
11/13/2310-Q1Quantitative and Qualitative Disclosures About Market Risk
3/31/2310-K1Report of Independent Registered Public Accounting Firm (Pcaob Id 23 )
1Risk Factor Summary
11/13/2310-Q1Risk Factors
3/31/2310-K1Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
1Selected Financial Data
11/13/2310-Q1Signatures
1Unregistered Sales of Equity Securities and Use of Proceeds
3/31/2310-K1Unresolved Staff Comments
8/14/2310-Q1(a) Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022
5/12/2310-Q1(a) Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022
11/13/2310-Q1(a) Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022
1(b) Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2023 and 2022
8/14/2310-Q1(b) Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended June 30, 2023 and 2022
5/12/2310-Q1(b) Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022
11/13/2310-Q1(c) Condensed Consolidated Statements of Changes in Stockholders' Deficit for the nine months ended September 30, 2023 and 2022
8/14/2310-Q1(c) Condensed Consolidated Statements of Changes in Stockholders' Deficit for the six months ended June 30, 2023 and 2022
5/12/2310-Q1(c) Condensed Consolidated Statements of Changes in Stockholders' Deficit for the three months ended March 31, 2023 and 2022
11/13/2310-Q1(d) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022
8/14/2310-Q1(d) Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022
5/12/2310-Q1(d) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022
11/13/2310-Q1(e) Notes to Condensed Consolidated Financial Statements

Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 8:54:02.2am ET